Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Thrombocytopenia 1Purpura, Thrombocytopenic, Idiopathic 1Purpura, Thrombocytopenic 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Chemotherapy-induced Thrombocytopenia 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Platelet Transfusion 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2romiplostim 1oprelvekin 1lusutrombopag 1eltrombopag 1avatrombopag 1Interleukin-11 1Injections 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Thrombocytopenia × romiplostim × Clear all
NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen

Phase 3 Completed
62 enrolled 16 charts 1 FDA
Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡